Insider activity (SEC Form 4)
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
Open-market · last 30 days:
2 buyers bought $44K
0 sellers sold $0
Open-market · last 90 days:
2 buyers bought $1.2M
0 sellers sold $0
| Insider | Role | Date | Transaction | Shares | Value |
|---|
| Vivo Opportunity, LLC |
10% Owner |
2026-07-16 |
Open-market buy |
19 |
$29 |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-16 |
Open-market buy |
2 |
$3 |
| ADAR1 Capital Management, LLC |
10% Owner |
2026-07-15 |
Open-market buy |
1000 |
$2K |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-15 |
Open-market buy |
13761 |
$21K |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-15 |
Open-market buy |
1389 |
$2K |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-14 |
Open-market buy |
4882 |
$8K |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-14 |
Open-market buy |
493 |
$764 |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-02 |
Open-market buy |
1460 |
$2K |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-02 |
Open-market buy |
147 |
$228 |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-01 |
Open-market buy |
3946 |
$6K |
| Vivo Opportunity, LLC |
10% Owner |
2026-07-01 |
Open-market buy |
398 |
$617 |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-30 |
Open-market buy |
545 |
$839 |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-30 |
Open-market buy |
55 |
$85 |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-08 |
Open-market buy |
29518 |
$45K |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-08 |
Open-market buy |
2982 |
$5K |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-05 |
Open-market buy |
49966 |
$78K |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-05 |
Open-market buy |
5045 |
$8K |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-04 |
Open-market buy |
6125 |
$10K |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-04 |
Open-market buy |
618 |
$970 |
| Vivo Opportunity, LLC |
10% Owner |
2026-06-03 |
Open-market buy |
7069 |
$11K |
Most recent 20 reported transactions. Open-market buys (P) and sells (S) are the deliberate ones; grants and option exercises are compensation. Not investment advice.
8-K
filed 2026-07-22
confidence 94%
Item 8.01
InMed Pharmaceuticals is merging with Mentari Therapeutics in a transaction involving a two-step merger structure. The transaction includes a $200 million pre-closing private placement and a concurrent $290 million private placement, with the combined company to operate under the Mentari Therapeutics name and trade on Nasdaq Capital Market under a new ticker symbol. Post-closing, Mentari shareholders will own approximately 98.85% and InMed shareholders approximately 1.15% of the combined entity.
View raw filing on EDGAR →
8-K
filed 2026-07-10
confidence 95%
Item 1.01
InMed entered into Amendment No. 1 to its merger agreement with Mentari Therapeutics on July 6, 2026, amending the definitive merger agreement dated May 19, 2026 to clarify transaction sequencing, financing mechanics, and tax treatment. The all-stock merger constitutes a change of control and is expected to close in Q4 2026, subject to shareholder approval and other customary conditions.
View raw filing on EDGAR →
8-K
filed 2026-06-10
confidence 92%
Item 8.01
InMed received a Nasdaq notice on March 27, 2026 that its closing bid price fell below the $1.00 minimum requirement under Nasdaq Listing Rule 5550(a)(2), creating delisting risk. Although the Company subsequently regained compliance by June 3, 2026, the disclosure centers on the failure to satisfy a continued listing rule and the remediation thereof—the core substance of delisting_risk. This is material to investors as it directly affects the registrant's exchange listing status.
View raw filing on EDGAR →
8-K
filed 2026-05-19
confidence 85%
Item 1.01
InMed Pharmaceuticals amended preferred investment options with Armistice Capital, reducing the exercise price from $16.60 to $0.80 per share on 278,761 common shares. This substantial downward repricing converts out-of-the-money warrants into deeply in-the-money instruments, significantly increasing the likelihood of exercise and dilution to existing shareholders.
View raw filing on EDGAR →
8-K
filed 2026-05-19
confidence 96%
Item 1.01
InMed Pharmaceuticals entered into a definitive merger agreement with Mentari Therapeutics on May 19, 2026, whereby Mentari shareholders will receive approximately 98.49% of the combined company post-closing. The transaction contemplates a $125 million equity valuation for Mentari and involves a two-step merger structure with concurrent $150 million financing, constituting a material change of control requiring shareholder approval and SEC registration.
View raw filing on EDGAR →